Anti-Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander? [PDF]
Stalman AFL, van der Woude D.
europepmc +1 more source
HLA-DR risk variants in rheumatoid arthritis: what we know and still do not know. [PDF]
Yap CF, Viatte S.
europepmc +1 more source
Mapping the Substrate Specificity Landscape of PAD2 and PAD4 Enzymes. [PDF]
Borbély A +6 more
europepmc +1 more source
Tumor-infiltrating plasma cell targets as a source for immunotherapies. [PDF]
Lattanzi G, Hollern D.
europepmc +1 more source
Increased number of crosslinking sites for factor XIII counteracts the mechanical and lytic destabilization of fibrin caused by citrullination of fibrinogen. [PDF]
Guzmits K +4 more
europepmc +1 more source
Development of motif-specific monoclonal antibodies for global protein citrullination detection with minimal cross-reactivity to homocitrullination. [PDF]
Laposchan S +5 more
europepmc +1 more source
Proteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapy. [PDF]
Sharma P +8 more
europepmc +1 more source
The TG2/LRP1 Pathway for T Cell Activation by Post-Translationally Modified Antigens. [PDF]
Sewa AS, Yang FC, Khosla C.
europepmc +1 more source
Proteomic profiling of serum and saliva in rheumatoid arthritis: A pilot Q-TOF study. [PDF]
Pandarathodiyil AK +4 more
europepmc +1 more source
High-throughput chemical proteomics workflow for profiling protein citrullination dynamics. [PDF]
Meelker González R +10 more
europepmc +1 more source

